QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
QQQ   318.40 (-1.60%)
AAPL   125.12 (-2.09%)
MSFT   233.87 (-1.30%)
FB   259.00 (-2.23%)
GOOGL   2,064.48 (-0.25%)
TSLA   686.44 (-4.45%)
AMZN   3,094.53 (-1.64%)
NVDA   536.25 (-3.15%)
BABA   234.42 (-3.01%)
CGC   35.25 (+1.50%)
GE   12.98 (-0.99%)
MU   91.09 (-3.87%)
NIO   43.29 (-13.00%)
AMD   84.13 (-2.62%)
T   28.22 (+0.46%)
F   12.55 (+4.76%)
ACB   11.03 (-0.09%)
DIS   193.94 (-0.53%)
BA   223.14 (-0.56%)
NFLX   547.82 (-0.51%)
PFE   33.51 (-0.53%)
Log in
NASDAQ:ANGN

Angion Biomedica Stock Forecast, Price & News

$20.90
+0.98 (+4.92 %)
(As of 03/2/2021 12:00 AM ET)
Add
Compare
Today's Range
$20.00
Now: $20.90
$23.24
50-Day Range N/A
52-Week Range
$16.00
Now: $20.90
$26.30
Volume469,941 shs
Average Volume220,284 shs
Market Capitalization$600.27 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Angion Biomedica Corp., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3777, a hepatocyte growth factor mimetic for acute kidney injury, acute lung injury, acute respiratory distress syndrome, central nervous system injuries, and heart injuries. It also develops products, such as ANG-3070 tyrosine kinase inhibitor and rho kinase 2 inhibitor for fibrotic diseases; and CYP11B2, an aldosterone synthase inhibitor for aldosterone-related fibrotic diseases. The company was founded in 1998 and is headquartered in Uniondale, New York.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ANGN
CUSIPN/A
CIKN/A
Phone415 655 4899
EmployeesN/A
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$600.27 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

1.00 out of 5 stars

Medical Sector

990th out of 1,968 stocks

Biotechnology Industry

24th out of 124 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$20.90
+0.98 (+4.92 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive ANGN News and Ratings via Email

Sign-up to receive the latest news and ratings for ANGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Angion Biomedica (NASDAQ:ANGN) Frequently Asked Questions

Is Angion Biomedica a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Angion Biomedica in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Angion Biomedica stock.
View analyst ratings for Angion Biomedica
or view top-rated stocks.

What stocks does MarketBeat like better than Angion Biomedica?

Wall Street analysts have given Angion Biomedica a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Angion Biomedica wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Who are Angion Biomedica's key executives?

Angion Biomedica's management team includes the following people:
  • Dr. Itzhak D. Goldberg, Exec. Chairman & Chief Scientific Officer (Age 72, Pay $179.7k)
  • Dr. Jay R. Venkatesan M.B.A., M.D., Ph.D., Pres, CEO & Director (Age 49)
  • Mr. Gregory S. Curhan, Interim Chief Financial Officer (Age 59)
  • Ms. Jennifer J. Rhodes J.D., Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 51)
  • Dr. John F. Neylan, Sr. VP & Chief Medical Officer (Age 68)
  • Bruce Rich, Assistant Sec.

Who are some of Angion Biomedica's key competitors?

When did Angion Biomedica IPO?

(ANGN) raised $75 million in an IPO on Friday, February 5th 2021. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. Cowen and Stifel acted as the underwriters for the IPO and H.C. Wainwright & Co., LLC and Oppenheimer & Co. were co-managers.

What is Angion Biomedica's stock symbol?

Angion Biomedica trades on the NASDAQ under the ticker symbol "ANGN."

When does Angion Biomedica's quiet period expire?

Angion Biomedica's quiet period expires on Wednesday, March 17th. Angion Biomedica had issued 5,000,000 shares in its IPO on February 5th. The total size of the offering was $80,000,000 based on an initial share price of $16.00. During Angion Biomedica's quiet period, insiders and underwriters that worked on the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company's quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

How do I buy shares of Angion Biomedica?

Shares of ANGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Angion Biomedica's stock price today?

One share of ANGN stock can currently be purchased for approximately $20.90.

How much money does Angion Biomedica make?

Angion Biomedica has a market capitalization of $600.27 million.

What is Angion Biomedica's official website?

The official website for Angion Biomedica is www.angion.com.

How can I contact Angion Biomedica?

The company can be reached via phone at 415 655 4899.


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.